Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY REPORTED THE GRANT IN AUGUST OF AN AGGREGATE OF 12,731 RESTRICTED STOCK UNITS (RSUS) OF THE COMPANY'S COMMON STOCK TO 5 NEWLY HIRED NON-EXECUTIVE EMPLOYEES OF THE COMPANY. THE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS UNDER THE EVOLUS' 2023 INDUCEMENT INCENTIVE PLAN, WITH A GRANT D.

EVOLUS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED THE PUBLICATION OF A LANDMARK INDEPENDENT STUDY IN JAMA DERMATOLOGY DIRECTLY COMPARING FOUR LEADING BOTULINUM TOXIN TYPE A PRODUCTS FOR THE TREATMENT OF GLABELLAR LINES: JEUVEAU (PRABOTULINUMTOXINA-XVFS), BOTOX (ONABOTULINUMTOXINA), DYSPORT (ABOBOTULINUMTOXINA), AND XEOMIN (INCOBOTULINUMTOXINA). IN THE DOUBLE-BL.

EVOLUS ANNOUNCES PUBLICATION OF INDEPENDENT STUDY IN JAMA DERMATOLOGY DEMONSTRATING JEUVEAU AS A TOP PERFORMER AMONG LEADING NEUROTOXINS

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED THAT IT WILL REPORT ITS SECOND QUARTER 2025 FINANCIAL RESULTS ON TUESDAY, AUGUST 5, 2025, AFTER THE U.S. FINANCIAL MARKETS CLOSE. EVOLUS MANAGEMENT WILL HOST A CONFERENCE CALL AND LIVE WEBCAST TO DISCUSS THESE RESULTS AT 4:30 P.M. ET THAT SAME DAY. A QUESTION-AND-ANSWER SESSION WILL FOLLOW MANAGEMENT'S REMARKS. TO P.

EVOLUS TO REPORT SECOND QUARTER FINANCIAL RESULTS ON AUGUST 5, 2025

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY REPORTED THE GRANT IN JULY OF AN AGGREGATE OF 12,385 RESTRICTED STOCK UNITS (RSUS) OF THE COMPANY'S COMMON STOCK TO 6 NEWLY HIRED NON-EXECUTIVE EMPLOYEES OF THE COMPANY. THE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS UNDER THE EVOLUS' 2023 INDUCEMENT INCENTIVE PLAN, WITH A GRANT DAT.

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED IT HAS PARTNERED WITH SYMATESE TO COMMENCE DISTRIBUTION OF NUCEIVA (BOTULINUM TOXIN TYPE A) IN FRANCE. NUCEIVA IS APPROVED BY THE EUROPEAN COMMISSION FOR THE TEMPORARY IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE VERTICAL LINES BETWEEN THE EYEBROWS SEEN AT MAXIMUM FROWN (GLABELLAR LINES), WHEN THE SEVERITY.

EVOLUS EXPANDS GLOBAL FOOTPRINT WITH INTRODUCTION OF NUCEIVA (BOTULINUM TOXIN TYPE A) IN FRANCE

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY REPORTED THE GRANT IN JUNE OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 11,628 SHARES OF EVOLUS AND AN AGGREGATE OF 36,077 RESTRICTED STOCK UNITS (RSUS) OF THE COMPANY'S COMMON STOCK TO 17 NEWLY HIRED NON-EXECUTIVE EMPLOYEES OF THE COMPANY. THE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S.

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, IS PROUD TO ANNOUNCE IT HAS BEEN RECOGNIZED WITH TWO SHAPE 2025 SKIN AWARDS: EVOLYSSE RECOGNIZED AS THE BEST FILLER FOR 2025 WITH ITS RECENTLY LAUNCHED INJECTABLE HYALURONIC ACID GEL LINE BEST MEMBERSHIP TREATMENT MODEL FOR CLUB EVOLUS, ITS PROPRIETARY CONSUMER REWARDS PROGRAM THE ANNUAL SHAPE SKIN AWARDS HIGHLIGHT INNOVATION AND.

EVOLYSSE RECOGNIZED IN 2025 SHAPE SKIN AWARDS

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED THAT ITS CHIEF FINANCIAL OFFICER, SANDRA BEAVER, HAS RESIGNED EFFECTIVE JUNE 13, 2025, TO ACCEPT THE SAME POSITION AT A PRIVATE MENTAL HEALTH AND WELLNESS TECHNOLOGY COMPANY. MS. BEAVER'S RESIGNATION IS NOT A RESULT OF ANY DISAGREEMENT RELATED TO THE COMPANY'S OPERATIONS, POLICIES OR PRACTICES, INCLUDING ANY ACCOUNT.

EVOLUS ANNOUNCES DEPARTURE OF ITS CHIEF FINANCIAL OFFICER

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY ANNOUNCED THE PUBLICATION OF THE U.S. PIVOTAL STUDY RESULTS FOR EVOLYSSE FORM AND EVOLYSSE SMOOTH IN THE AESTHETIC SURGERY JOURNAL, A LEADING PEER-REVIEWED JOURNAL FOCUSING ON ADVANCES IN AESTHETIC MEDICINE AND SURGERY. THE MULTICENTER, RANDOMIZED, CONTROLLED, DOUBLE-BLIND STUDY FOLLOWED 140 PATIENTS THROUGH 12 MONTHS AND E.

EVOLUS ANNOUNCES PUBLICATION OF U.S. PIVOTAL STUDY FOR EVOLYSSE FORM AND EVOLYSSE SMOOTH INJECTABLE HYALURONIC ACID GELS

NEWPORT BEACH, CALIF.--(BUSINESS WIRE)--EVOLUS, INC. (NASDAQ: EOLS), A PERFORMANCE BEAUTY COMPANY WITH A FOCUS ON BUILDING AN AESTHETIC PORTFOLIO OF CONSUMER BRANDS, TODAY REPORTED THE GRANT IN MAY OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 12,706 SHARES OF EVOLUS AND AN AGGREGATE OF 40,576 RESTRICTED STOCK UNITS (RSUS) OF THE COMPANY'S COMMON STOCK TO 16 NEWLY HIRED NON-EXECUTIVE EMPLOYEES OF THE COMPANY. THE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S B.

Evolus, Inc.

EOLS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Evolus, Inc.

EOLS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

EOLS